Literature DB >> 26697575

Clinical Diagnosis and Staging of Intrahepatic Cholangiocarcinoma.

Isabel Bartella1, Jean-François Dufour2.   

Abstract

Intrahepatic cholangiocarcinomas are the second most common primary liver malignancies with an increasing incidence over the past decades. Due to a lack of early symptoms and their aggressive oncobiological behavior, the diagnostic approach is challenging and the outcome remains unsatisfactory with a poor prognosis. Thus, a consistent staging system for a comparison between different therapeutic approaches is needed, but independent predictors for worse survival are still controversial. Currently, four different staging systems are primarily used, which differ in the way they determine the 'T' category. Furthermore, different nomograms and prognostic models have been recently proposed and may be helpful in providing additional information for predicting the prognosis and therefore be helpful in approaching an adequate treatment strategy. This review will discuss the diagnostic approach to intrahepatic cholangiocarcinoma as well as compare and contrast the most current staging systems and prognostic models.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26697575     DOI: 10.15403/jgld.2014.1121.244.chl

Source DB:  PubMed          Journal:  J Gastrointestin Liver Dis        ISSN: 1841-8724            Impact factor:   2.008


  19 in total

1.  Implications of CA19-9 elevation for survival, staging, and treatment sequencing in intrahepatic cholangiocarcinoma: A national cohort analysis.

Authors:  John R Bergquist; Tommy Ivanics; Curtis B Storlie; Ryan T Groeschl; May C Tee; Elizabeth B Habermann; Rory L Smoot; Michael L Kendrick; Michael B Farnell; Lewis R Roberts; Gregory J Gores; David M Nagorney; Mark J Truty
Journal:  J Surg Oncol       Date:  2016-07-20       Impact factor: 3.454

Review 2.  Staging of intrahepatic cholangiocarcinoma.

Authors:  Sean M Ronnekleiv-Kelly; Timothy M Pawlik
Journal:  Hepatobiliary Surg Nutr       Date:  2017-02       Impact factor: 7.293

Review 3.  Therapeutic options for intrahepatic cholangiocarcinoma.

Authors:  Manojkumar Bupathi; Daniel H Ahn; Tanios Bekaii-Saab
Journal:  Hepatobiliary Surg Nutr       Date:  2017-04       Impact factor: 7.293

Review 4.  Intrahepatic Cholangiocarcinoma.

Authors:  Pouya Entezari; Ahsun Riaz
Journal:  Semin Intervent Radiol       Date:  2020-12-11       Impact factor: 1.513

5.  Scalp recurrence of cholangiocarcinoma after curative hepatectomy: A report of two cases.

Authors:  Enver Kunduz; Kursat Rahmi Seri N; Mesut Seker
Journal:  Mol Clin Oncol       Date:  2017-10-23

6.  The anticancer effects of Resina Draconis extract on cholangiocarcinoma.

Authors:  Feng Wen; Xiangxuan Zhao; Yun Zhao; Zaiming Lu; Qiyong Guo
Journal:  Tumour Biol       Date:  2016-09-28

7.  MicroRNA-26b-5p regulates cell proliferation, invasion and metastasis in human intrahepatic cholangiocarcinoma by targeting S100A7.

Authors:  Fei Fan; Jiongjiong Lu; Wenlong Yu; Yongjie Zhang; Suqian Xu; Leilei Pang; Bin Zhu
Journal:  Oncol Lett       Date:  2017-11-02       Impact factor: 2.967

8.  Bioinformatics Analysis Identifies the Estrogen Receptor 1 (ESR1) Gene and hsa-miR-26a-5p as Potential Prognostic Biomarkers in Patients with Intrahepatic Cholangiocarcinoma.

Authors:  Xianzheng Qin; Yuning Song
Journal:  Med Sci Monit       Date:  2020-05-21

Review 9.  Primary or metastatic hepatic carcinoma? A breast cancer patient after adjuvant chemotherapy and radiotherapy postoperatively with intrahepatic cholangiocarcinoma and review of the literature.

Authors:  Zhao-Yun Liu; Ju-Jie Sun; Ke-Wen He; Pei-Ying Zhuo; Zhi-Yong Yu
Journal:  World J Surg Oncol       Date:  2016-07-15       Impact factor: 2.754

10.  ACGH detects distinct genomic alterations of primary intrahepatic cholangiocarcinomas and matched lymph node metastases and identifies a poor prognosis subclass.

Authors:  Ruben Jansen; Birte Moehlendick; Christoph Bartenhagen; Csaba Tóth; Nadja Lehwald; Nikolas H Stoecklein; Wolfram T Knoefel; Anja Lachenmayer
Journal:  Sci Rep       Date:  2018-07-13       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.